GlycoErase™ AGL Knockout Glycoengineered Cell (CAT#: GLJF-0825-JF3)

Description	GlycoErase™ AGL knockout glycoengineered cell disrupts glycogen debrancher enzyme activity, which combines 4-alpha-glucotransferase and amylo-1,6-glucosidase functions critical for glycogen breakdown. Knocking out AGL allows exploration of glycogen metabolism, energy regulation, and disease mechanisms such as glycogen storage disorders. This model provides a tool for metabolic research and drug development.
Product Type	KO Cell Lines
Cell Line	As requested by the client.

Cell Viability	>90%
Sterility Test	The sterility test indicated an absence of microbial growth.
Identity Test	STR identification
Mycoplasma Test	Negative
Virus Test	Negative for HIV, HBV and HCV.
Genetic Stability Testing	We conduct cell genetic stability studies in full compliance with ICH guidelines. Our expertise enables us to design and execute a comprehensive testing program tailored to your specific needs and regulatory requirements.
Validation	PCR, Sanger Sequencing
Application	Functional assay
Size	1 M cells/vial*2
Product Format	Frozen
Shipping	Dry ice
Availability Status	Made to order
Handling Notes	Upon receipt, this product must be immediately transferred from dry ice to liquid nitrogen (-150°C to -190°C) and stored in a liquid nitrogen tank. Cell viability is critically dependent on proper handling. We cannot guarantee viability if these instructions are not strictly adhered to.
Product Disclaimer	This product is provided for research only, not suitable for human or animal use. Due to the inherent limitations of infectious agent testing, investigators must exercise extreme caution when handling cells provided by Creative Biolabs, treating all cells as potentially biohazardous.

Target	AGL
Full Name	Amylo-Alpha-1, 6-Glucosidase, 4-Alpha-Glucanotransferase
Alternative Name	GDE
Location	1p21.2
Gene ID	178
Summary	This gene encodes the glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in this gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing. Alternatively spliced transcripts encoding different isoforms have been described.